IB Net Payout Yields Model

Novavax: Watch For Delays

Novavax (NVAX) is expected to provide data this week for the Phase 1/2 flu study. The only problem is that the results were originally expected by the end of 2017.

Novavax CEO Stanley Erck made the following statement on the Q3'17 earnings call:

Investors need to note that this statement was made on November 7. In less than 60 days, Novavax missed the deadline by at least 50 days. The small biotech has a history of missing deadlines on a continual basis while hyping 'hot' vaccines.

When the company does report the data on the NanoFlu vaccine, investors need to pay attention to the meaningful milestones provides by management. Watch the pre-BLA status shift into 2019 and don't expect any FDA approval before 2020, if ever.

The flu vaccine is in demand now, but naturally Novavax has no product inline for approval any time soon. The stock though could rally on any positive spin by the company. Be careful holding the stock after the rally.

Disclosure: No position. Please review the disclaimer page for more details. 


Popular posts from this blog

Aurora Cannabis: Deal Or No Deal

Celsius: Unaltered Growth Story

Hims & Hers Health: Still Firing On Strong Cylinders